What's Happening?
Charles River Laboratories has highlighted the effectiveness of Virtual Control Groups (VCGs) in toxicology studies. A retrospective analysis published in Regulatory Toxicology and Pharmacology demonstrated that VCGs can maintain scientific integrity
while reducing the reliance on animal models. The study reviewed 20 toxicology studies where VCGs replaced concurrent control groups, showing 100% concordance in the No Observed Adverse Effect Level (NOAEL) across all studies. This approach combines historical data with advanced analytics, offering a modern alternative to traditional methods.
Why It's Important?
The use of VCGs represents a significant step forward in toxicology research, aligning with ethical considerations to reduce animal use in scientific studies. This method not only preserves scientific validity but also enhances study efficiency and data interpretability. By reducing the number of animals used in research, VCGs support the 3Rs principle (replacement, reduction, refinement) in scientific research. This advancement could lead to more predictive and efficient safety assessments, benefiting pharmaceutical and biotechnology industries by accelerating drug development processes.
What's Next?
Charles River Laboratories is committed to further refining VCG models to address any endpoint-level variability observed in studies. The company is also collaborating with regulatory agencies to establish qualification standards for VCGs, aiming for broader acceptance and implementation in toxicology research. This ongoing effort is part of a larger initiative to modernize nonclinical safety assessments and reduce reliance on animal testing, potentially setting new industry standards for ethical and efficient research practices.
